Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

IsraelCompletedPHASE2

Conditions

Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Pacific Cancer Medical Center Inc, Anaheim, California, United States

  • Loma Linda University Cancer Center, Loma Linda, California, United States

  • Ucla Department Of Medicine, Los Angeles, California, United States

  • Stanford University School Of Medicine, Stanford, California, United States

  • Kaiser Permanente Medical Center, Vallejo, California, United States

  • H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

  • University Of Chicago, Chicago, Illinois, United States

  • Central Indiana Cancer Centers, Indianapolis, Indiana, United States

  • University Of Kansas Medical Center, Westwood, Kansas, United States

  • Dana Faber Cancer Institute, Boston, Massachusetts, United States

  • University Of Michigan Medical Center, Ann Arbor, Michigan, United States

  • Wayne State University, Detroit, Michigan, United States

  • John Theurer Cancer Center, Hackensack, New Jersey, United States

  • Oregon Health & Sci Univ, Portland, Oregon, United States

  • Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States

  • Ut Southwestern Medical Center At Dallas, Dallas, Texas, United States

  • The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States

  • Local Institution, Buenos Aires, Buenos Aires, Argentina

  • Local Institution, Buenos Aires, Buenos Aires, Argentina

  • Local Institution, Capital Federal, Buenos Aires, Argentina

  • Local Institution, Adelaide, South Australia, Australia

  • Local Institution, Mont-godinne, Belgium

  • Local Institution, Curitiba, Paraná, Brazil

  • Local Institution, Rio de Janeiro, Rio de Janeiro, Brazil

  • Local Institution, Campinas, São Paulo, Brazil

  • Local Institution, São Paulo, São Paulo, Brazil

  • Local Institution, São Paulo, São Paulo, Brazil

  • Local Institution, Toronto, Ontario, Canada

  • Local Institution, Montreal, Quebec, Canada

  • Local Institution, Helsinki, Finland

  • Local Institution, Lille, France

  • Local Institution, Lyon, France

  • Local Institution, Nantes, France

  • Local Institution, Paris, France

  • Local Institution, Pessac, France

  • Local Institution, Poitiers, France

  • Local Institution, Strasbourg, France

  • Local Institution, Hamburg, Germany

  • Local Institution, Leipzig, Germany

  • Local Institution, Mannheim, Germany

  • Local Institution, Budapest, Hungary

  • Local Institution, Dublin, Dublin, Ireland

  • Local Institution, Ramat Gan, Israel

  • Local Institution, Bologna, Italy

  • Local Institution, Naples, Italy

  • Local Institution, Orbassano (to), Italy

  • Local Institution, Roma, Italy

  • Local Institution, Trondheim, Norway

  • Local Institution, Lima, Lima Province, Peru

  • Local Institution, Lima, Lima Province, Peru

  • Local Institution, Katowice, Poland

  • Local Institution, Krakow, Poland

  • Local Institution, Lodz, Poland

  • Local Institution, Lublin, Poland

  • Local Institution, Warsaw, Poland

  • Local Institution, Moscow, Russia

  • Local Institution, Saint Petersburg, Russia

  • Local Institution, Groenkloof, Gauteng, South Africa

  • Local Institution, Parktown, Gauteng, South Africa

  • Local Institution, Jeollanam-do, South Korea

  • Local Institution, Seoul, South Korea

  • Local Institution, Barcelona, Spain

  • Local Institution, Gothenburg, Sweden

  • Local Institution, Lund, Sweden

  • Local Institution, Stockholm, Sweden

  • Local Institution, Umeå, Sweden

  • Local Institution, Uppsala, Sweden

  • Local Institution, Basel, Switzerland

  • Local Institution, Bangkok, Thailand

  • Local Institution, London, Greater London, United Kingdom

  • Local Institution, Glasgow, Scotland, United Kingdom

  • Local Institution, Newcastle, Tyne and Wear, United Kingdom

Study leads
  • Bristol-Myers Squibb

    Study Director

    Bristol-Myers Squibb